Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer’s Disease and Related Dementias (R01 Clinical Trial Not Allowed) - PAR-25-374
Funder
National Institutes of Health
LOI Required
No
Application Deadline
;
;
;
;
;
;
;
;
Maximum Project Duration
5 years
Research Focus Areas
Pharmacotherapy
Pharmacology
Molecular and Cellular
Alzheimer’s Disease, Dementia, and Neurocognitive Disorders
Bioinformatics
Research Methods
Computational Biology
Animal Models
Description
This Notice of Funding Opportunity (NOFO) invites applications that combine computational and experimental approaches to enable rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in Alzheimer's Disease (AD) and AD-related dementias (ADRD). This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes. The central goal of this NOFO is to establish robust proof of concept in mouse models or cell-based models of AD/ADRD that will enable rational drug repositioning and the development of precision combination therapies for the treatment and prevention of AD/ADRD.